3 Beaten-Down Biotech Stocks to Buy Right Now

Biotech stocks that crater on negative clinical results or unfavorable regulatory developments can sometimes represent outstanding investing opportunities. Not all beaten-down biotech stocks, though, are diamonds in the rough. 

Among the 15 biotech companies that saw their shares slide by more than 10% last month, for instance, I'd personally only consider buying shares of three: Intercept Pharmaceuticals (NASDAQ: ICPT), Exelixis (NASDAQ: EXEL), and Sage Therapeutics (NASDAQ: SAGE). Here's why. 

Image Source: Getty Images.

Continue reading


Source: Fool.com